On the gefitinib retreatment in patients with advanced non-small cell lung cancer.docVIP

 PAGE \* MERGEFORMAT 14 On the gefitinib retreatment in patients with advanced non-small cell lung cancer [Paper Keywords] Gefitinib; non-small cell lung cancer; targeted therapy [Abstract] Objective: To advanced non-small cell lung cancer (non-small cell lung cancer, NSCLC) after application of gefitinib efficacy and toxicity were observed. Methods: 8 cases of stage Ⅳ hospital for treatment of non-small cell lung cancer, and are surgery, radiotherapy, chemotherapy and other treatment failure cases. Gefitinib monotherapy for the treatment of oral 250 mg, 1 times / d, until death or serious adverse reactions or disease progression. The whole group the median time of medication was 8.6 months. Results: 8 patients, 4 cases of partial remission (PR), 2 patients with stable (NC), 2 patients with progressive (PD); symptom relief in 6 cases, to alleviate the most obvious symptoms of suffocation, cough and pain, relief of symptoms median time 14 d. The most common side effects were easy to control and reverse the skin rash and diarrhea. Conclusions: Oral gefitinib monotherapy for after surgery, radiotherapy and chemotherapy failed NSCLC is effective and has a good tolerance. Rate of increase in incidence of lung cancer ranks the first place. Despite surgery, chemotherapy, radiotherapy and other measures continue to develop, but with advanced non-small cell lung cancer (NSCLC) the prognosis remains poor, the cure rate is less than 15% [1]. Targeted therapy of lung cancer clinical trials in recent years into a new treatment approach to the treatment offers new hope. The representation of molecular targeted therapy drugs tyrosine kinase receptor inhibitor gefitinib (Gefitinib, ZD1839, trade name: Iressa) is one of them, for the treatment of past received chemotherapy for locally advanced or metastatic non - small-cell lung cancer, it is based on epidermal growth factor receptor (EGFR) as the target drugs. Preliminary clinical trials have proved the me